Literature DB >> 9221805

Disease expression in Swiss hereditary non-polyposis colorectal cancer (HNPCC) kindreds.

K Heinimann1, H Müller, W Weber, R J Scott.   

Abstract

The genetics of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) has recently been established and found to be associated with DNA mismatch repair deficiency. As the molecular basis of this syndrome does not appear to predict any particular disease, we compared families selected according to the "Amsterdam" criteria (AC) against families that were selected because of an aggregation of colonic and extracolonic malignancies (EC), all of which have been observed in HNPCC families. A comparison of the 2 groups revealed that there were significant differences between them. Age at disease onset for both groups was 20-30 years younger than in the general population; however, a normal age distribution was observed for the AC group whereas for the EC group a bimodal distribution was apparent. The prognosis for both groups together did not differ from that of the general population; however, if split, the AC group had a significantly better outcome than the EC group. Furthermore, dividing the AC group into hMSH2- and hMLH1-linked families revealed that there was no difference in severity of disease between these 2 groups with respect to survival and mean age of disease onset. Both the AC and EC groups displayed a similar tumour spectrum with a virtually identical tumour distribution. A significant finding was the over-representation, of brain tumours in this family set, which comprised the third most common malignancy after endometrial and stomach cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9221805     DOI: 10.1002/(sici)1097-0215(19970620)74:3<281::aid-ijc8>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer.

Authors:  Mark A Jenkins; Melissa C Southey; Graham G Giles; John L Hopper
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

Review 2.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

3.  Primary sclerosing epithelioid fibrosarcoma of the lung in a patient with Lynch syndrome.

Authors:  Priska Leisibach; Walter Weder; Alex Soltermann; Wolfgang Jungraithmayr
Journal:  Lung       Date:  2012-07-06       Impact factor: 2.584

4.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.

Authors:  A R Brooks-Wilson; P Kaurah; G Suriano; S Leach; J Senz; N Grehan; Y S N Butterfield; J Jeyes; J Schinas; J Bacani; M Kelsey; P Ferreira; B MacGillivray; P MacLeod; M Micek; J Ford; W Foulkes; K Australie; C Greenberg; M LaPointe; C Gilpin; S Nikkel; D Gilchrist; R Hughes; C E Jackson; K G Monaghan; M J Oliveira; R Seruca; S Gallinger; C Caldas; D Huntsman
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

5.  Microsatellite instability and mutation of DNA mismatch repair genes in gliomas.

Authors:  S Y Leung; T L Chan; L P Chung; A S Chan; Y W Fan; K N Hung; W K Kwong; J W Ho; S T Yuen
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  Johanne Geary; Peter Sasieni; Richard Houlston; Louise Izatt; Ros Eeles; Stewart J Payne; Samantha Fisher; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2007-10-16       Impact factor: 2.375

7.  DNA Methylation Identifies Loci Distinguishing Hereditary Nonpolyposis Colorectal Cancer Without Germ-Line MLH1/MSH2 Mutation from Sporadic Colorectal Cancer.

Authors:  Chung-Hsing Chen; Shih Sheng Jiang; Ling-Ling Hsieh; Reiping Tang; Chao A Hsiung; Hui-Ju Tsai; I-Shou Chang
Journal:  Clin Transl Gastroenterol       Date:  2016-12-15       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.